Novel linear DNA vaccines induce protective immune responses against lethal infection with influenza virus type A/H5N1

Frédéric Kendirgi, Nadezda E. Yun, Nathaniel S. Linde, Michele A. Zacks, Jeanon N. Smith, Jennifer K. Smith, Harilyn McMicken, Yin Chen, Slobodan Paessler

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Vaccine development for possible influenza pandemics has been challenging. Conventional vaccines such as inactivated and live attenuated virus preparations are limited in terms of production speed and capacity. DNA vaccination has emerged as a potential alternative to conventional vaccines against influenza pandemics. In this study, we use a novel, cell-free DNA manufacturing process (synDNA™) to produce prototype linear DNA vaccines against the influenza virus type A/H5N1. This synDNA™ process does not require bacterial fermentation, so it avoids the use of antibiotic resistance genes and other nucleic acid sequences unrelated to the antigen gene expression in the actual therapeutic DNA construct. The efficacy of various vaccines expressing the hemagglutinin and neuraminidase proteins (H5N1 synDNA™), hemagglutinin alone (H5 synDNA™) or neuraminidase alone (N1 synDNA™) was evaluated in mice. Two of the constructs (H5 synDNA™ and H5N1 synDNA™) induced a robust protective immune response with up to 93% of treated mice surviving a lethal challenge of a virulent influenza A/Vietnam/1203/04 H5N1 isolate. In combination with a potent biological activity and simplified production footprint, these characteristics make DNA vaccines prepared with our synDNA™ process highly suitable as alternatives to other vaccine preparations.

Original languageEnglish (US)
Pages (from-to)410-419
Number of pages10
JournalHuman Vaccines
Volume4
Issue number6
StatePublished - 2008

Fingerprint

DNA Vaccines
Influenza A virus
Hemagglutinins
Vaccines
Neuraminidase
Pandemics
Infection
Human Influenza
DNA
Vietnam
Influenza Vaccines
Microbial Drug Resistance
Nucleic Acids
Fermentation
Vaccination
Viruses
Gene Expression
Antigens
Genes
Proteins

Keywords

  • Cell-free DNA vaccine production
  • DNA vaccine
  • Immune response
  • Influenza virus type A/H5N1
  • SynDNA™ vaccine

ASJC Scopus subject areas

  • Immunology
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Kendirgi, F., Yun, N. E., Linde, N. S., Zacks, M. A., Smith, J. N., Smith, J. K., ... Paessler, S. (2008). Novel linear DNA vaccines induce protective immune responses against lethal infection with influenza virus type A/H5N1. Human Vaccines, 4(6), 410-419.

Novel linear DNA vaccines induce protective immune responses against lethal infection with influenza virus type A/H5N1. / Kendirgi, Frédéric; Yun, Nadezda E.; Linde, Nathaniel S.; Zacks, Michele A.; Smith, Jeanon N.; Smith, Jennifer K.; McMicken, Harilyn; Chen, Yin; Paessler, Slobodan.

In: Human Vaccines, Vol. 4, No. 6, 2008, p. 410-419.

Research output: Contribution to journalArticle

Kendirgi, F, Yun, NE, Linde, NS, Zacks, MA, Smith, JN, Smith, JK, McMicken, H, Chen, Y & Paessler, S 2008, 'Novel linear DNA vaccines induce protective immune responses against lethal infection with influenza virus type A/H5N1', Human Vaccines, vol. 4, no. 6, pp. 410-419.
Kendirgi F, Yun NE, Linde NS, Zacks MA, Smith JN, Smith JK et al. Novel linear DNA vaccines induce protective immune responses against lethal infection with influenza virus type A/H5N1. Human Vaccines. 2008;4(6):410-419.
Kendirgi, Frédéric ; Yun, Nadezda E. ; Linde, Nathaniel S. ; Zacks, Michele A. ; Smith, Jeanon N. ; Smith, Jennifer K. ; McMicken, Harilyn ; Chen, Yin ; Paessler, Slobodan. / Novel linear DNA vaccines induce protective immune responses against lethal infection with influenza virus type A/H5N1. In: Human Vaccines. 2008 ; Vol. 4, No. 6. pp. 410-419.
@article{3ea817e6c1494721b1fd63cdb93f462c,
title = "Novel linear DNA vaccines induce protective immune responses against lethal infection with influenza virus type A/H5N1",
abstract = "Vaccine development for possible influenza pandemics has been challenging. Conventional vaccines such as inactivated and live attenuated virus preparations are limited in terms of production speed and capacity. DNA vaccination has emerged as a potential alternative to conventional vaccines against influenza pandemics. In this study, we use a novel, cell-free DNA manufacturing process (synDNA™) to produce prototype linear DNA vaccines against the influenza virus type A/H5N1. This synDNA™ process does not require bacterial fermentation, so it avoids the use of antibiotic resistance genes and other nucleic acid sequences unrelated to the antigen gene expression in the actual therapeutic DNA construct. The efficacy of various vaccines expressing the hemagglutinin and neuraminidase proteins (H5N1 synDNA™), hemagglutinin alone (H5 synDNA™) or neuraminidase alone (N1 synDNA™) was evaluated in mice. Two of the constructs (H5 synDNA™ and H5N1 synDNA™) induced a robust protective immune response with up to 93{\%} of treated mice surviving a lethal challenge of a virulent influenza A/Vietnam/1203/04 H5N1 isolate. In combination with a potent biological activity and simplified production footprint, these characteristics make DNA vaccines prepared with our synDNA™ process highly suitable as alternatives to other vaccine preparations.",
keywords = "Cell-free DNA vaccine production, DNA vaccine, Immune response, Influenza virus type A/H5N1, SynDNA™ vaccine",
author = "Fr{\'e}d{\'e}ric Kendirgi and Yun, {Nadezda E.} and Linde, {Nathaniel S.} and Zacks, {Michele A.} and Smith, {Jeanon N.} and Smith, {Jennifer K.} and Harilyn McMicken and Yin Chen and Slobodan Paessler",
year = "2008",
language = "English (US)",
volume = "4",
pages = "410--419",
journal = "Human Vaccines",
issn = "1554-8600",
publisher = "Landes Bioscience",
number = "6",

}

TY - JOUR

T1 - Novel linear DNA vaccines induce protective immune responses against lethal infection with influenza virus type A/H5N1

AU - Kendirgi, Frédéric

AU - Yun, Nadezda E.

AU - Linde, Nathaniel S.

AU - Zacks, Michele A.

AU - Smith, Jeanon N.

AU - Smith, Jennifer K.

AU - McMicken, Harilyn

AU - Chen, Yin

AU - Paessler, Slobodan

PY - 2008

Y1 - 2008

N2 - Vaccine development for possible influenza pandemics has been challenging. Conventional vaccines such as inactivated and live attenuated virus preparations are limited in terms of production speed and capacity. DNA vaccination has emerged as a potential alternative to conventional vaccines against influenza pandemics. In this study, we use a novel, cell-free DNA manufacturing process (synDNA™) to produce prototype linear DNA vaccines against the influenza virus type A/H5N1. This synDNA™ process does not require bacterial fermentation, so it avoids the use of antibiotic resistance genes and other nucleic acid sequences unrelated to the antigen gene expression in the actual therapeutic DNA construct. The efficacy of various vaccines expressing the hemagglutinin and neuraminidase proteins (H5N1 synDNA™), hemagglutinin alone (H5 synDNA™) or neuraminidase alone (N1 synDNA™) was evaluated in mice. Two of the constructs (H5 synDNA™ and H5N1 synDNA™) induced a robust protective immune response with up to 93% of treated mice surviving a lethal challenge of a virulent influenza A/Vietnam/1203/04 H5N1 isolate. In combination with a potent biological activity and simplified production footprint, these characteristics make DNA vaccines prepared with our synDNA™ process highly suitable as alternatives to other vaccine preparations.

AB - Vaccine development for possible influenza pandemics has been challenging. Conventional vaccines such as inactivated and live attenuated virus preparations are limited in terms of production speed and capacity. DNA vaccination has emerged as a potential alternative to conventional vaccines against influenza pandemics. In this study, we use a novel, cell-free DNA manufacturing process (synDNA™) to produce prototype linear DNA vaccines against the influenza virus type A/H5N1. This synDNA™ process does not require bacterial fermentation, so it avoids the use of antibiotic resistance genes and other nucleic acid sequences unrelated to the antigen gene expression in the actual therapeutic DNA construct. The efficacy of various vaccines expressing the hemagglutinin and neuraminidase proteins (H5N1 synDNA™), hemagglutinin alone (H5 synDNA™) or neuraminidase alone (N1 synDNA™) was evaluated in mice. Two of the constructs (H5 synDNA™ and H5N1 synDNA™) induced a robust protective immune response with up to 93% of treated mice surviving a lethal challenge of a virulent influenza A/Vietnam/1203/04 H5N1 isolate. In combination with a potent biological activity and simplified production footprint, these characteristics make DNA vaccines prepared with our synDNA™ process highly suitable as alternatives to other vaccine preparations.

KW - Cell-free DNA vaccine production

KW - DNA vaccine

KW - Immune response

KW - Influenza virus type A/H5N1

KW - SynDNA™ vaccine

UR - http://www.scopus.com/inward/record.url?scp=56149116696&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56149116696&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 410

EP - 419

JO - Human Vaccines

JF - Human Vaccines

SN - 1554-8600

IS - 6

ER -